Present and emerging therapies for multiple sclerosis

CONTINUUM Lifelong Learning in Neurology

Volumn 19, Issue 4, 2013, Pages 968-991

  Freedman, Mark S ^a,b  

^a UNIVERSITY OF OTTAWA   (Canada)

^b OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ACICLOVIR; ALEMTUZUMAB; BETA INTERFERON; BETA1A INTERFERON; DACLIZUMAB; DRUG METABOLITE; FINGOLIMOD; FUMARIC ACID DIMETHYL ESTER; FUMARIC ACID METHYL ESTER; GLATIRAMER; INTERFERON BETA SERINE; LAQUINIMOD; NATALIZUMAB; OCRELIZUMAB; PLACEBO; TERIFLUNOMIDE; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ADD ON THERAPY; ALLERGIC ENCEPHALOMYELITIS; ALLERGIC REACTION; ANAPHYLAXIS; ANXIETY; AUTOIMMUNE DISEASE; AUTOIMMUNE THROMBOCYTOPENIA; BACKACHE; BLOOD CELL COUNT; CARDIOVASCULAR DISEASE; CHEST TIGHTNESS; CHRONIC LYMPHATIC LEUKEMIA; COLON CANCER; DEPRESSION; DIAPHORESIS; DIARRHEA; DISEASE COURSE; DRUG APPROVAL; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG ELIMINATION; DRUG EXCRETION; DRUG MECHANISM; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; DYSPNEA; ERYTHEMA; FATIGUE; FLU LIKE SYNDROME; FLUSHING; GASTROINTESTINAL SYMPTOM; GLOMERULONEPHRITIS; GOODPASTURE SYNDROME; HAIR DISEASE; HEADACHE; HEART PALPITATION; HERPES SIMPLEX; HUMAN; INFECTION; INFUSION RELATED REACTION; INJECTION SITE REACTION; LEUKOPENIA; LIPOATROPHY; LIVER DISEASE; LIVER FUNCTION TEST; LIVER TOXICITY; LOW DRUG DOSE; LUNG DISEASE; MOUTH INFECTION; MULTIPLE SCLEROSIS; NAUSEA; NEUROLOGIC DISEASE; PANCYTOPENIA; PERIPHERAL EDEMA; PHARYNGITIS; PHASE 3 CLINICAL TRIAL (TOPIC); PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; PRURITUS; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECOMMENDED DRUG DOSE; REVIEW; RHINOPHARYNGITIS; SIDE EFFECT; SINUS CONGESTION; SKIN CARCINOMA; SKIN INDURATION; SKIN NECROSIS; SPASTICITY; SQUAMOUS CELL CARCINOMA; TERATOGENICITY; THYROID CANCER; THYROID DISEASE; THYROID PAPILLARY CARCINOMA; THYROTOXICOSIS; TREATMENT OUTCOME; UPPER ABDOMINAL PAIN; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; URTICARIA;

ADMINISTRATION, ORAL; ADULT; ANTIBODIES, MONOCLONAL; FEMALE; HUMANS; IMMUNOLOGIC FACTORS; IMMUNOSUPPRESSIVE AGENTS; INJECTIONS; MALE; MULTIPLE SCLEROSIS; YOUNG ADULT;

EID: 84881626451     PISSN: 10802371     EISSN: 15386899     Source Type: Journal    
DOI: 10.1212/01.CON.0000433288.30715.e3     Document Type: Review

References (47)

1. Chen SJ, Wang YL, Fan HC, et al. Current status of the immunomodulation and immunomediated therapeutic strategies for multiple sclerosis. Clin Dev Immunol 2012; 2012:970789.
2. Nicholas R, Giannetti P, Alsanousi A, et al. Development of oral immunomodulatory agents in the management of multiple sclerosis. Drug Des Devel Ther 2011;5: 255-274.
3. Rudick RA, Stuart WH, Calabresi PA, et al. Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N Engl J Med 2006;354(9):911-923.
4. Giovannoni G, Southam E, Waubant E. Systematic review of disease-modifying therapies to assess unmet needs in multiple sclerosis: tolerability and adherence. Mult Scler 2012;18(7):932-946.
5. Dhib-Jalbut S. Mechanisms of action of interferons and glatiramer acetate in multiple sclerosis. Neurology 2002; 58(8 suppl 4):S3-S9.
6. Interferon beta-1b in the treatment of multiple sclerosis: final outcome of the randomized controlled trial. IFNB Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group. Neurology 1995;45(7):1277-1285.
7. Jacobs LD, Cookfair DL, Rudick RA, et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Ann Neurol 1996;39(3):285-294.
8. Simon JH, Jacobs LD, Campion M, et al. Magnetic resonance studies of intramuscular interferon beta-1a for relapsing multiple sclerosis. Ann Neurol 1998;43(1):79-87.
9. Randomized double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group. Lancet 1998;352(9139):1498-1504.
10. Li DK, Paty DW. Magnetic resonance imaging results of the PRISMS trial: a randomized, double-blind, placebo-controlled study of interferon-beta1a in relapsingremitting multiple sclerosis. Prevention of Relapses and Disability by Interferon-beta1a Subcutaneously in Multiple Sclerosis. Ann Neurol 1999;46(2):197-206.
11. Polman CH, Bertolotto A, Deisenhammer F, et al. Recommendations for clinical use of data on neutralising antibodies to interferon-beta therapy in multiple sclerosis. Lancet Neurol 2010;9(7):740-750.
12. Bornstein MB, Miller A, Slagle S, et al. A pilot trial of Cop 1 in exacerbating-remitting multiple sclerosis. N Engl J Med 1987; 317(7):408-414.
13. Johnson KP, Brooks BR, Cohen JA, et al. Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind, placebocontrolled trial. The Copolymer 1 Multiple Sclerosis Study Group. Neurology 1995; 45(7):1268-1276.
14. Comi G, Filippi M, Wolinsky JS, et al. European/Canadian multicenter, double-blind, randomized, placebocontrolled study of the effects of glatiramer acetate on magnetic resonance imagingV measured disease activity and burden in patients with relapsing multiple sclerosis. European/Canadian Glatiramer Acetate Study Group. Ann Neurol 2001;49(3): 290-297.
15. Filippi M, Rovaris M, Rocca MA, et al. Glatiramer acetate reduces the proportion of new MS lesions evolving into "black holes". Neurology 2001;57(4):731-733.
16. Khan O, Rieckmann P, Boyko A, et al. A phase III trial to assess the efficacy and safety of glatiramer acetate injections 40 mg three times a week compared to placebo. Lyons, France: ECTRIMS, 2012.
17. Ransohoff RM. Natalizumab for multiple sclerosis. N Eng J Med 2007;356(25): 2622-2629.
18. Polman CH, O'Connor PW, Hardova E, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2006;354(9):899-910.
19. Miller DH, Soon D, Fernando KT, et al. MRI outcomes in a placebo-controlled trial of natalizumab in relapsing MS. Neurology 2007;68(17):1390-1401.
20. Calabresi PA, Giovannoni G, Confavreux C, et al. The incidence and significance of anti-natalizumab antibodies: results from AFFIRM and SENTINEL. Neurology 2007; 69(14):1391-1403.
21. Khatri BO, Man S, Giaovannoni G, et al. Effect of plasma exchange in accelerating natalizumab clearance and restoring leukocyte function. Neurology 2009;72(5): 402-409.
22. Kappos L, Bates D, Hartung HP, et al. Natalizumab treatment for multiple sclerosis: recommendations for patient selection and monitoring. Lancet Neurol 2007;6(5):431-441.
23. Pelletier D, Hafler DA. Fingolimod for multiple sclerosis. N Engl J Med 2012;366(4): 339-347.
24. Kappos L, Radue EW, O'Connor P, et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med 2010;362(5):387-401.
25. Cohen JA, Barkhof F, Comi G, et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med 2010;362(5):402-415.
26. O'Connor P, Wolinsky JS, Confavreux C, et al. Randomized trial of oral teriflunomide for relapsing multiple sclerosis. N Engl J Med 2011;365(14):1293-1303.
27. Miller AE, O'Connor P, Wolinsky JS, et al. Pre-specified subgroup analyses of a placebo-controlled phase III trial (TEMSO) of oral teriflunomide in relapsing multiple sclerosis. Mult Scler 2012;18(11):1625-1632.
28. Miller A, Kappos L, Comi G, et al. Teriflunomide efficacy and safety in patients with relapsing multiple sclerosis: results from TOWER, a second, pivotal, phase 3 placebo-controlled study (S01.004). Neurology 2013;80(meeting abstracts 1): S01.004.
29. Vermersch P, Czlonkowska P, Grimali LM, et al. A multicenter, randomized, parallel-group, rater-blinded study comparing the effectiveness and safety of teriflunomide and subcutaneous interferon beta-1a in patients with relapsing multiple sclerosis. Presented at: Fourth Cooperative Meeting of the Consortium of Multiple Sclerosis Centers and Americas Committee for Treatment and Research in Multiple Sclerosis; May 30 to June 2, 2012; San Diego, CA.
30. Gold R, Linker RA, Stangel M. Fumaric acid and its esters: an emerging treatment for multiple sclerosis with antioxidative mechanism of action. Clin Immunol 2012; 142(1):44-48.
31. Gold R, Kappos L, Arnold DL, et al. Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. N Engl J Med 2012;367(12):1098- 1107.
32. Fox RJ, Miller DH, Phillips JT, et al. Placebo-controlled phase 3 study of oral BG-12 or glatiramer in multiple sclerosis. N Engl J Med 2012;367(12):1087-1097.
33. Sweetser MT, Dawson KT, Bozic C. Manufacturer's Response to Case Reports of PML. N Engl J Med 2013;368(17):1659-1661.
34. Thone J, Ellrichmann G, Seubert S, et al. Modulation of autoimmune demyelination by laquinimod via induction of brain-derived neurotrophic factor. Am J Pathol 2012;180(1):267-274.
35. Comi G, Jeffery D, Kappos L, et al. Placebo-controlled trial of oral laquinimod for multiple sclerosis. N Engl J Med 2012; 366(11):1000-1009.
36. Vollmer TL, Soelberg Sorenson P, Arnold DL (on behalf of the BRAVO Study Group). A placebo-controlled and active comparator phase III trial (BRAVO) for relapsingremitting multiple sclerosis. Presented at: 5th Joint Triennial Congress of the European and Americas Subcommittees for Treatment and Research in Multiple Sclerosis; October 22, 2011; Amsterdam, The Netherlands.
37. Cohen JA, Coles AJ, Arnold DL, et al. Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial. Lancet 2012;380(9856):1819- 1828.
38. Coles AJ, Twyman CL, Arnold DL, et al. Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial. Lancet 2012;380(9856):1829-1839.
39. Fox EJ, Sullivan HC, Gazda SK, et al. A single-arm, open-label study of alemtuzumab in treatment-refractory patients with multiple sclerosis. Eur J Neurol 2012;19(2):307-311.
40. Sheridan JP, Zhang Y, Riester K, et al. Intermediate-affinity interleukin-2 receptor expression predicts CD56(bright) natural killer cell expansion after daclizumab treatment in the CHOICE study of patients with multiple sclerosis. Mult Scler 2011;17(12):1441-1448.
41. Wynn D, Kaufman M, Montalban X, et al. Daclizumab in active relapsing multiple sclerosis (CHOICE study): a phase 2, randomised, double-blind, placebocontrolled, add-on trial with interferon beta. Lancet Neurol 2010;9(4):381-390.
42. Gold R, Giovannoni G, Selmaj K, et al; SELECT Study Investigators. Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECT): a randomised, double-blind, placebo-controlled trial [published online ahead of printApril 3, 2013]. Lancet. doi:10.1016/S0140-6736(12)62190-4.
43. Hauser SL, Waubant E, Arnold DL, et al. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med 2008;358(7):676-688.
44. Kappos L, Li D, Calabresi PA, et al. Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial. Lancet 2011;378(9805):1779-1787.
45. Goodin DS. Disease-modifying therapy in multiple sclerosis: update and clinical implications. Neurology 2008;71(24 suppl 3): S8-S13.
46. Kieseier BC, Wiendl H, Hartung HP, et al. Risks and benefits of multiple sclerosis therapies: need for continual assessment? Curr Opin Neurol 2011;24(3):238-243.
47. Kieseier BC, Stuve O. A critical appraisal of treatment decisions in multiple sclerosis Vold versus new. Nat Rev Neurol 2011;7(5):255-262.